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Background: Despite evidence that erythropoietin and intra- and postoperative blood salvage are expensive
techniques considered to be non-cost-effective in primary elective total hip and knee arthroplasties in the
Netherlands, Dutch medical professionals use them frequently to prevent the need for allogeneic transfusion.
To actually change physicians’ practice, a tailored strategy aimed at barriers that hinder physicians in abandoning
the use of erythropoietin and perioperative blood salvage was systematically developed. The study aims to examine
the effectiveness, feasibility and costs of this tailored de-implementation strategy compared to a control strategy.
Methods/Design: A cluster randomized controlled trial including an effect, process and economic evaluation will
be conducted in a minimum of 20 Dutch hospitals. Randomisation takes place at hospital level. The hospitals in the
intervention group will receive a tailored de-implementation strategy that consists of four components: interactive
education, feedback in educational outreach visits, electronically sent reports on hospital performance (all aimed at
orthopedic surgeons and anesthesiologists), and information letters or emails aimed at other involved professionals
within the intervention hospital (transfusion committee, OR-personnel, pharmacists). The hospitals in the control
group will receive a control strategy (i.e., passive dissemination of available evidence). Outcomes will be measured
at patient level, using retrospective medical record review. This will be done in all hospitals at baseline and after
completion of the intervention period. The primary outcome of the effect evaluation is the percentage of patients
undergoing primary elective total hip or knee arthroplasty in which erythropoietin or perioperative blood salvage
is applied. The actual exposure to the tailored strategy and users’ experiences will be assessed in the process evaluation.
In the economic evaluation, the costs of the tailored strategy and the control strategy in relation to the difference in their
effectiveness will be compared.
Discussion: This study will show whether a systematically developed tailored strategy is more effective for
de-implementation of non-cost-effective blood saving measures than the control strategy. This knowledge can be used
in national and international initiatives to make healthcare more efficient. It also provides more generalized knowledge
regarding de-implementation strategies.
Trial registration: This trial is registered at the Dutch Trial Register NTR4044.
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Total joint replacement surgery such as total hip arthro-
plasty (THA) and total knee arthroplasty (TKA) is asso-
ciated with intra- and postoperative blood loss leading
to postoperative anemia. This can be subsequently
treated with allogeneic blood transfusion [1,2]. Yet, allo-
geneic blood transfusions carry the risk of infections and
non-infectious transfusion reactions [3]. Therefore, dif-
ferent types of blood saving measures (BSMs) have been
developed to reduce blood loss or to increase cell mass
to avoid allogeneic transfusions [4].
Many studies on the effectiveness of the frequently
used BSMs erythropoietin (EPO) and intra- and postop-
erative drainage and re-infusion of autologous blood (in
short: perioperative blood salvage) in orthopedic surgery
have been performed. Reviews and meta-analyses
showed that EPO and perioperative blood salvage reduce
transfusions. However, the included studies had several
limitations such as a retrospective design, small patient
numbers and poor methodologically quality leading to
bias in favor of EPO and perioperative blood salvage
[1,5-10]. When the costs of these techniques are consid-
ered, the use of EPO and perioperative blood salvage
becomes controversial [8,11-17]. A large multicenter
Randomized Controlled Trial (RCT) was recently per-
formed to test the effectiveness and cost-effectiveness of
EPO and perioperative blood salvage in elective THA
and TKA [18,19]. It was shown that perioperative blood
salvage in primary THA and TKA neither resulted in a
decreased mean number of allogeneic blood units nor in
a decrease in the proportion of transfused patients, and
was more expensive due to the costs of the device and a
prolonged hospital stay. EPO showed a significant de-
crease in the mean number of allogeneic blood units and
proportion of transfused patients, but the costs of this
technique were considered too high. It was thus con-
cluded that EPO and perioperative blood salvage were not
cost-effective in primary elective THA and TKA. For the
use of EPO and perioperative blood salvage in revision
THA and TKA no conclusions about the (cost-) effective-
ness could be drawn [18,19]. These results are in line with
recent literature. A number of trials that were not in-
cluded in the currently available meta-analyses show that
perioperative blood salvage is not superior to a regular
drain or no drain in THA or TKA [20-24], other studies
concerning the costs of EPO also doubt the cost-
effectiveness in orthopedic surgery [11,14].
Despite the evidence, medical professionals keep using
these BSMs in daily practice. Over 85% of Dutch hospi-
tals frequently use EPO, perioperative blood salvage, or a
combination of these in elective orthopaedic surgery
[25]. This leads to unnecessary healthcare costs. So, to
improve the efficiency of care delivery, a strategy is
needed aimed at barriers and facilitators to stop usingthese non-cost-effective BSMs (de-implementation strat-
egy) [26-29]. In the ‘Leiden Implementation Study of
BlOod management in hip and knee Arthroplasties’
(LISBOA I) problem analysis study [30], such a strategy
was developed in accordance with the implementation
model of Grol [31]. This model, as with other theories of
change, emphasizes that changes in current practice can
only take place after the current barriers and facilitators
for change have been identified and targeted. Therefore,
prior inventory of barriers and facilitators incorporated
in a tailored strategy can reduce the number of costly
trials evaluating different implementation strategies
[31-33]. The current study will test the hypothesis
that the developed strategy is more effective for de-
implementation of EPO and perioperative blood salvage
in elective primary THA and TKA in comparison with a
control strategy (i.e., passive dissemination of evidence).Objective
The ‘Leiden Implementation Study of BlOod management
in hip and knee Arthroplasties, part two’ (LISBOA-II)
aims to assess the effectiveness, feasibility and costs of
a systematically developed tailored strategy for de-
implementation of EPO and perioperative blood salvage in
primary elective THA and TKA [30] compared to a con-
trol strategy in a cluster randomized trial.Methods
Study design
A cluster randomized controlled trial including an
effect-, process- and economic evaluation will be con-
ducted in a minimum of 20 hospitals in the Netherlands
using EPO and/or perioperative blood salvage in THA
and TKA. Per hospital a representative orthopedic
surgeon will be invited to participate in the study (see
Additional file 1 for CONSORT checklist); consent of
hospitals willing to participate will be gathered according
to local hospital regulations. To prevent contamination
bias, randomisation will take place at the hospital level
stratified by geographic location of the hospitals. Ran-
domisation will be performed by an independent re-
searcher using a computer generated randomisation
table concealed in a sealed envelope. The randomisation
result will be revealed to the investigators and participat-
ing hospitals after the baseline measurement on effect
outcomes takes place.
This trial compares:
1. The tailored strategy to de-implement use of EPO
and perioperative blood salvage, and
2. A control strategy.
See Figure 1 for a flow-chart of the study design.
Baseline measurement on effect outcomes










Effect, process and cost measurements
Analysis and reporting
 
Figure 1 Flow-chart study design.
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Tailored de-implementation strategy
The tailored de-implementation strategy in intervention
hospitals is aimed at the barriers for de-implementation
of non-cost-effective BSMs as identified in our problem
analysis study, in which representative samples of ortho-
pedic surgeons and anesthesiologists participated
[30,34]. To ensure that we identified all relevant barriers,
we used the Theoretical Domains Framework (TDF)
[35-37]. The TDF includes 12 different domains derived
from a large number of health psychology theories and
their theoretical constructs. The main barriers to stop
using non-cost-effective BSMs in elective orthopedic
surgery were perceived by physicians within the follow-
ing domains of the TDF:
1. Knowledge: lack of alternatives, lack of interest to
gain additional information about stopping EPO and
perioperative blood salvage.
2. Motivation & goals: lack of interest to save money
for the society/ hospital, lack of benefit for the
delivery of care.
3. Beliefs about consequences: pressure of suppliers to
use BSMs, concerns about losing experience withthe use of BSMs, concerns about the safety of
patients when BSMs are stopped.
4. Social influences: the impact of blood management
policy of other medical specialties/ blood transfusion
committee, lack of influence of individual physician
on blood management policy.
Barriers for EPO and perioperative blood salvage
are largely similar and found within the same
domains. Some barriers are more relevant for de-
implementation of perioperative blood salvage (for ex-
ample, concerns about losing experience with the use
of BSMs) than for de-implementation of EPO. How-
ever, due to the large extent of overlap of barriers
and the similar target groups, we developed a com-
bined tailored strategy.
The developed tailored de-implementation strategy
consists of four components carried out in a period of
nine months. Every component targets one or more do-
mains on which barriers have been identified [35].
1. Interactive education for orthopedic surgeons and
anesthesiologists with a single visit in intervention
month 1 (to target the domain: motivation & goals).
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orthopedic surgeons and anesthesiologists with a
single visit in intervention months 5/6 (to target the
domain: beliefs about consequences).
3. Dissemination of reports on hospital performance
(BSM use and transfusion percentage) and
comparison with hospitals that do not use EPO or
perioperative blood salvage, e.g., ‘best practices,’ to
orthopedic surgeons and anesthesiologists with two
electronic newsletters sent in intervention months 4
to 6 and 7 to 9 (to target the domain: social
influences).
4. Email with available evidence to other involved
professionals, e.g., transfusion committee, OR-
personnel, pharmacists with a single newsletter sent
in intervention months 1 or 2 (to target the do-
mains: knowledge, motivation and goals, and beliefs
about consequences).




- Lack of interest to save money for 
the society/ hospital
- Lack of benefit for delivery of care
Beliefs about consequences
- Pressure of suppliers to use BSMs
- Concerns about losing experience 
with the use of BSMs
- Concerns about the safety of 
patients when BSMs are stopped
Social Influences
- Impeded by blood management 
policy of other medical specialties/ 
blood transfusion committee







Goal specified (desired 
behavior)
Knowledge
- Lack of alternatives
- Lack of interest to gain additional 
information about stopping BSMs
Barriers
Figure 2 De-implementation strategy. 1Technique: the behavior change
the technique will be delivered. 3Content: what will be delivered.Control strategy
The control strategy consists of the passive dissemin-
ation of evidence via publication in scientific journals
indexed for PubMed. No further actions to make the
control hospitals aware of the published evidence will be
undertaken. After the post-intervention measurement
period, we will offer the control hospitals the possibility
to have the interactive education as described for the
intervention hospitals and a report on their hospital per-
formance in comparison with best practices.
Study population
All types of hospitals (university hospitals, teaching hos-
pitals, general hospitals and private clinics) that fre-
quently use BSMs [25] will be invited to participate in
this study. Further, we have previously shown that blood
transfusion committees, hospital boards, patients, and
other stakeholders are involved in blood management,
but do not make decisions regarding the use of BSMs in
THA and TKA [34]. Therefore, the de-implementation






reports on hospital 
performance/ best 
practices
Target group: blood transfusion committee, OR 
personnel, pharmacists.
Timing: at start of intervention.
By whom: research team.
Content:
- Overview literature about cell salvage and 
use of EPO in TKA en THA.





Target group: anesthesiologists/ orthopedic 
surgeons.
Timing: at start of intervention.
By whom: research team.
Duration: 1 hour.
Content:
- Overview literature about cell salvage and 
use of EPO in TKA en THA).
- (Benefits of a) cost-effective transfusion 
policy.
- Casuistry/ small assignments.
- Distribution of pocket cards with cost-
effective transfusion policy.
Target group: anesthesiologists/ orthopedic 
surgeons.
Timing: half-way the intervention period.
By whom: research team.
Duration: 1 hour.
Content:
- Feedback about use of BSMs, transfusion 
rates, complications (transfusion/ BSM 
related), length of stay, costs.
- Discussion about casuistry, patient safety, 
and limited benefits of BSMs.
Target group: anesthesiologists/ orthopedic 
surgeons.
Timing: 2-3 x during intervention period.
By whom: research team.
Content:
- News mails with information on hospital 
performance on implementation (in 
comparison to other hospitals) and best 
practices.
technique used to overcome the identified barrier. 2Mode: the way
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with one strategy-component aimed at other involved
professionals.
See Table 1 for in- and exclusion criteria for the par-
ticipating hospitals and patients.
Evaluation and outcome measures
1. Effect evaluation
The effect of the tailored strategy will be compared
with the control strategy before and after carrying out
the strategy. Outcomes will be measured at patient level,
using retrospective medical record review at least three
weeks postoperative with standardized registration
forms. Measurement periods last for five months.
Within each month, medical records of at least 10 con-
secutively treated patients will be reviewed in each par-
ticipating hospital, with a maximum of 20 patients per
month (depending on the number of patients treated
within that month).
Primary outcome
The primary outcome is the % of patients undergoing
primary elective total THA or TKA in which EPO or
perioperative blood salvage is applied.
Secondary outcomes
Secondary outcomes are the patient outcomes of the
surgery including: Post-operative hemoglobin (Hb) level,
length of hospital stay and number of allogeneic redTable 1 In- and exclusion criteria for participating hospitals a
Inclusion criteria Excl
Participating hospitals
• Hospitals using EPO and/or blood salvage in patients
undergoing primary elective THA or TKA on a regular basis
(more frequently than in exceptional cases)
• Ho
or b
• Hospitals performing at least 50 THA






• Patients scheduled for primary elective THA or TKA • Bila







• Patblood cell transfusions. Adverse events will also be regis-
tered: reactions on EPO use, transfusion reactions due
to the use of perioperative blood salvage, transfusion re-
actions due to allogeneic transfusions and complications
registered in patients’ medical records.
Other parameters measured in this study are patient
characteristics (age, sex, BMI, ASA-classification, and
pre-operative Hb), techniques used during the surgical
procedure (type of anesthesia, use of tourniquet in TKA,
surgical approach, use of other BSMs, use of drains) and
postoperative care (postoperative blood loss, re-infusion
of salvaged blood, type and length of postoperative
anticoagulation).
2. Process evaluation
A process evaluation will be performed to assess the
feasibility of the de-implementation strategy in compari-
son with the control strategy. Such an evaluation gives
insight into the mechanisms and processes responsible for
the effect of the de-implementation strategy and the con-
trol strategy [38]. The actual ‘exposure’ of clinicians to the
elements of the de-implementation strategy, together with
their experience with these elements, may influence the
final results. At the end of the study period, experiences of
clinicians with the elements of the de-implementation
strategy will be measured using questionnaires, to further
improve the de-implementation strategy for future use (if
necessary). In these questionnaires, we will also ask about
the presence and their awareness of barriers for behavior
change.nd patients
usion criteria
spitals considering abandoning the use of EPO
lood salvage on their own initiative
spitals participating in trials that interfere with the use or
iscontinuation of EPO or blood salvage
spitals employing the same group of orthopaedic surgeons
aesthesiologists as a previously included hospital
teral surgery
ients with a malignancy (except skin cancer or cured cancers)
erious disorder of the coronary, peripheral and/or carotid arteries,
ent myocardial infarction or CVA (past 6 months)
treated hypertension (diastolic BP >95 mmHg)
ients with a pregnancy
ients with a coagulation disorder
ients refusing or with a contraindication for allogeneic blood transfusions
ients with untreated anaemia Hb <10 g/dl
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changes in staff, changes in blood management, changes
in surgical techniques and local initiatives to optimize
THA and TKA care will be registered in both study
arms. See also Table 2.
3. Economic evaluation
The economic evaluation will compare the costs of
both de-implementation strategies in relation to their
difference in effects. The analyses will not be performed
separately for the de-implementation of EPO and peri-
operative blood salvage since it is impossible to deter-
mine which costs of the de-implementation strategy are
exclusively made for the de-implementation of EPO and
for the de-implementation of perioperative blood sal-
vage. The economic evaluation will be performed from a
healthcare perspective. No discounting will be applied
due to the short time frame of the study.
The implementation costs concern the cost of execution
of the de-implementation strategy [39], which consist of
material costs (e.g., education material, information letter),
and personnel cost (e.g., hours for the team of investiga-
tors conducting the strategy, hours of orthopedic
surgeons and anesthesiologists attending the strategy-
related activities). Resource use will be measured by
questionnaires to the clinicians involved. For the valu-
ation of the resource use, market prices (material) and
wages including holiday allowance and social charges
(personnel costs) are used [40].
Table 2 provides an overview of all measurements.
Statistical analysis
All data will be entered and stored in an electronic data-
base. Descriptive statistics include frequencies, percent-
ages, medians, means and SDs. Hospital and patient
characteristics of study hospitals will be compared using








On patient level (through retrospective chart review)
Primary and secondary outcomes, complications and adverse events x
Patient characteristics x
Techniques during surgical procedure x
Postoperative care xfor continuous variables and χ2-test for proportions. The
overall effect of the intervention will be evaluated by
comparing the average outcome in the control hospitals
with the average outcome in the intervention hospitals.
The effects on the percentage of patients receiving a
THA or TKA in which BSMs (stratified to the % pa-
tients with EPO and % patients with perioperative blood
salvage) are applied will be adjusted for clustering of pa-
tients in hospitals. Therefore, multilevel logistic regres-
sion analysis will be performed. Analyses will be based
on the intention to treat principle, meaning that all par-
ticipating hospitals will be included in the study arm
(control or intervention) to which they are originally
assigned, regardless of whether they participated in the
components of the tailored strategy.
Sample size
We expect to detect an absolute difference of at least
20% in BSM use between the group receiving the de-
implementation strategy and the control group. We as-
sume that frequent BSM use, as assessed in the Dutch
survey [25], means that BSMs are applied in 50% of the
patients. To detect a difference of 20% (from 50% to
30%), with alpha 0.05, a two-sided testing and power of
80%, an intra-cluster-correlation coefficient of 0.08, 50
patients per hospital and 20 hospitals are needed (total
of 1,000 patients). Given the 70% of hospitals in The
Netherlands frequently applying BSMs [25], this means
that 69 hospitals are eligible for the present study. Since
the average hospital performs about 550 total hip and
knee arthroplasties per year, it is feasible to include 20
hospitals and at least 50 patients per hospital in
5 months, before and after the intervention period.
Ethical approval
The Medical Ethical Committee of the Leiden University
Medical Center decided that ethical approval was not re-








x x x x
x x x x
x x x x
x x x x
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conducted in compliance with the Good Clinical
Practices protocol and Declaration of Helsinki principles
[41].
Trial status
The LISBOA II study started in March 2013. The prep-
aration of the study components and the recruitment of
hospitals to participate in the study were completed in
September 2013. The baseline data collection in all hos-
pitals was performed from September 2013 until January
2014. Currently (March 2014), the intervention period is
ongoing.
Discussion
The goal of this study is to test a tailored strategy to let
physicians stop using EPO and perioperative blood sal-
vage in primary elective THA and TKA, i.e., the de-
implementation of non-cost-effective BSMs. This study
is the next step following a RCT on EPO and periopera-
tive blood salvage as transfusion alternatives in THA
and TKA using a restrictive transfusion policy, showing
that use of these BSMs is not cost-effective [18,19], and
a study in which a tailored de-implementation strategy
was systematically developed [25,30,34]. Given the large
number of THA and TKA performed annually in
the Netherlands and worldwide, de-implementation of
non-cost effective BSMs contributes to more efficient
healthcare.
A strength of this study is that it is one of the first
studies that assesses the effect of a de-implementation
strategy. The study results will thus lead to generalizable
knowledge regarding de-implementation strategies of
non-cost-effective interventions and how this differs
from strategies for implementation. This knowledge is
useful to contain healthcare spending and optimize out-
comes [26,27].
A possible limitation of the study is the awareness of
the study purpose among physicians within the control
group. During the recruitment of hospitals for participa-
tion in our study, hospitals cannot be blinded to the aim
of this study. Physicians want to know the study goal be-
fore giving approval for participation in a study. As a
consequence, physicians of control hospitals are actively
made aware of the fact that they deliver non-efficient
care and thereby can make changes in their blood man-
agement policy. This does not resemble ‘standard prac-
tice’ in hospitals not participating in a study and may
lead to a smaller difference in the effect between the
intervention and control hospitals. We will try to limit
this awareness by asking the study coordinators of each
participating hospital not to inform their staff members
(orthopedic surgeons and anesthesiologists) about the
study.A second limitation is bias as a result of local initia-
tives to optimize care for THA and TKA during the
intervention period. For example, the implementation of
‘fast track’ or ‘joint care’ programs for THA and TKA
may lead to abandoning perioperative blood salvage be-
cause of logistic reasons. Therefore, information on
local, non-study related changes will be additionally
inquired during the process evaluation.
Our study will not only demonstrate whether a tai-
lored strategy to de-implement BSMs is effective, feas-
ible and cost-effective compared to the control strategy,
but will also contribute to general knowledge regarding
differences between de-implementation and implemen-
tation strategies. Little is known about strategies to ef-
fectively de-implement common practices, for instance,
whether de-implementation strategies should also be
constructed following the same theoretical models and
frameworks as implementation. It is likely that it is far
more attractive for clinicians to implement something
new than to de-implement something expensive or inef-
fective [26,27]. Our study will thus not only assess
whether a tailored strategy to de-implement BSMs is
effective, feasible and cost-effective compared to the
control strategy, but will also contribute to general
knowledge regarding differences between de-implementation
and implementation strategies.
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